经PCS区域动脉灌注健择和5-氟尿嘧啶治疗中晚期胰腺癌的疗效观察  

Trans-port-catheter System Arterial Infusion of Gemcitabine and 5-fluorouracil for Treatment of Advanced Pancreatic Cancer

作　　者：吴建兵[1] 黄平[1] 王顺金[1] 周华兰[1] 李凌[1] 

机构地区：[1]江西医学院第二附属医院肿瘤科,南昌330006

出　　处：《肿瘤防治研究》2004年第5期298-300,共3页Cancer Research on Prevention and Treatment

摘　　要：目的　评价经PCS区域动脉灌注健择和 5 氟尿嘧啶治疗中晚期胰腺癌的疗效和安全性。方法　 36例中晚期胰腺癌患者分为 2组 ,16例行经PCS区域动脉灌注化疗 (B组 ) ,另 2 0例行外周静脉全身化疗 (A组 )。结果　B组临床受益反应有效率为 75 .0 % (12 / 16 ) ,A组为 4 5 .0 % (9/ 2 0 ) (P <0 .0 5 ) ,A组和B组 6个月、1年生存率和中位生存期分别为 35 .0 %、15 .0 %、6 .8个月和 6 8.7%、37.5 %、11.4个月 ,P<0 .0 5。结论　经PCS区域动脉灌注化疗较外周静脉化疗能提高中晚期胰腺癌的临床受益反应、改善生活质量 ,提高远期生存率。Objective The aim of the study was to assess the effect and security of gemcitabine and 5-fluorouracil by Trans-port-catheter system arterial infusion chemotherapy on pancreatic cancer. Methods 36 cases of advanced pancreatic cancer were divided into two groups,16 cases were treated with Trans-port-catheter system arterial infusion chemotherapy (group B),other 20 cases were treated with systemic chemotherapy (group A). Results The clinical benefit response rate of the group B was 75.0% (12/16) and that of the group A was 45.0% (9/20) ( P < 0.05 ). The 6-month,1-year survival rates and median survival of group A were 35.0% , 15.0% and 6.8 month;in the contrary,those of group B were 68.7% ? 37.5% and 11.4 month( P < 0.05 ).Conclusion The treatment of Trans-port-catheter system arterial infusion chemotherapy could effectively increase clinical benefit response,survival rate and improve the quality of life of advanced pancreatic cancer.

关 键 词：经PCS区域 动脉灌注 5-氟尿嘧啶 晚期 胰腺癌 胰腺肿瘤 消化道肿瘤 

分 类 号：R735.9[医药卫生—肿瘤]